Vertex (VRTX -1.4%) dips on an earlier downgrade to Neutral at Credit Suisse, citing lower sales...

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex (VRTX -1.4%) dips on an earlier downgrade to Neutral at Credit Suisse, citing lower sales forecasts for Incivek given Gilead (GILD) new competition and expectations for significant warehousing pressure on margins. The firm also lowers its price target to $48 from $56.